Epstein Secrets

pproximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events." Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a

uction with Evolocumab Reply-To: Cardiology Alert <I Email not displaying correctyNiaw it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study. presented at the 2

pproximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events." Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a

cumab Reply-To: Cardiology Alert < EFTA00447987 Entail not displaying coirectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2

approximately 50% higher than had been postulated led to a shorter required duration of follow-up to accrue the prespecified number of events' Dr. Sabatine emphasized the importance of aggressive LDL-lowering treatment in the future. "We need to treat LDL cholesterol more aggressively, and now we have a

eduction with Evolocumab Reply-To: Cardiology Alert E— ail not displaying conectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2